CK2 inhibitors increase the sensitivity of HSV-1 to interferon-β

Antiviral Research

Volumn 91, Issue 3, 2011, Pages 259-266

  Smith, Miles C ^a   Bayless, Adam M ^a   Goddard, Erica T ^a   Davido, David J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Ad5; CK2; HSV 1; ICP0; IFN; VSV

Indexed keywords

BETA INTERFERON; CASEIN KINASE II; DNA DEPENDENT PROTEIN KINASE; PROMYELOCYTIC LEUKEMIA PROTEIN; TRANSACTIVATOR PROTEIN; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; DEGRADATION; ENZYME ACTIVE SITE; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; VESICULAR STOMATITIS; VESICULAR STOMATITIS VIRUS; VIROGENESIS; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TYPING;

ADENOVIRIDAE; ANTIVIRAL AGENTS; BLOTTING, WESTERN; CASEIN KINASE II; CELL LINE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERFERON-BETA; LUNG; MICROSCOPY, FLUORESCENCE; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; VESICULOVIRUS; VIRUS REPLICATION;

HUMAN ADENOVIRUS TYPE 5; HUMAN HERPESVIRUS 1; VESICULAR STOMATITIS VIRUS;

EID: 79960441542     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.06.009     Document Type: Article

References (52)

1. Ahmad K.A., Wang G., Slaton J., Unger G., Ahmed K. Targeting CK2 for cancer therapy. Anticancer Drugs 2005, 16:1037-1043.
2. Allende J.E., Allende C.C. Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB J. 1995, 9:313-323.
3. Anderson K.P., Fennie E.H. Adenovirus early region 1A modulation of interferon antiviral activity. J. Virol. 1987, 61:787-795.
4. Bates P.A., DeLuca N.A. The polyserine tract of herpes simplex virus ICP4 is required for normal viral gene expression and growth in murine trigeminal ganglia. J. Virol. 1998, 72:7115-7124.
5. Boutell C., Everett R.D., Hilliard J., Schaffer P.A., Orr A., Davido D.J. Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner. J. Virol. 2008, 82:10647-10656.
6. Briggs L.J., Johnstone R.W., Elliot R.M., Xiao C.Y., Dawson M., Trapani J.A., Jans D.A. Novel properties of the protein kinase CK2-site-regulated nuclear-localization sequence of the interferon-induced nuclear factor IFI 16. Biochem. J. 2001, 353:69-77.
7. Cai W.Z., Schaffer P.A. Herpes simplex virus type 1 ICP0 plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA. J. Virol. 1989, 63:4579-4589.
8. Chelbi-Alix M.K., de Thé H. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 1999, 18:935-941.
9. Conner J. The unique N terminus of herpes simplex virus type 1 ribonucleotide reductase large subunit is phosphorylated by casein kinase 2, which may have a homologue in Escherichia coli. J. Gen. Virol. 1999, 80:1471-1476.
10. Corbin-Lickfett K.A., Rojas S., Li L., Cocco M.J., Sandri-Goldin R.M. ICP27 phosphorylation site mutants display altered functional interactions with cellular export factors Aly/REF and TAP/NXF1 but are able to bind herpes simplex virus 1 RNA. J. Virol. 2010, 84:2212-2222.
11. Critchfield J.W., Coligan J.E., Folks T.M., Butera S.T. Casein kinase II is a selective target of HIV-1 transcriptional inhibitors. Proc. Natl. Acad. Sci. USA 1997, 94:6110-6115.
12. Das S.C., Nayak D., Zhou Y., Pattnaik A.K. Visualization of intracellular transport of vesicular stomatitis virus nucleocapsids in living cells. J. Virol. 2006, 80:6368-6377.
13. Davido D.J., von Zagorski W.F., Lane W.S., Schaffer P.A. Phosphorylation site mutations affect herpes simplex virus type 1 ICP0 function. J. Virol. 2005, 79:1232-1243.
14. Eidson K.M., Hobbs W.E., Manning B.J., Carlson P., DeLuca N.A. Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection. J. Virol. 2002, 76:2180-2191.
15. Elliott G., O'Reilly D., O'Hare P. Identification of phosphorylation sites within the herpes simplex virus tegument protein VP22. J. Virol. 1999, 73:6203-6206.
16. Everett R.D., Rechter S., Papior P., Tavalai N., Stamminger T., Orr A. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. 2006, 80:7995-8005.
17. Fields B.N., Knipe D.M., Howley P.M., Griffin D.E. Fields Virology 2007, Lippincott Williams & Wilkins.
18. Härle P., Sainz B., Carr D.J.J., Halford W.P. The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-α/β. Virology 2002, 293:295-304.
19. Halford W.P., Kemp C.D., Isler J.A., Davido D.J., Schaffer P.A. ICP0, ICP4, or VP16 expressed from adenovirus vectors induces reactivation of latent herpes simplex virus type 1 in primary cultures of latently infected trigeminal ganglion cells. J. Virol. 2001, 75:6143-6153.
20. Haller O., Kochs G., Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology 2006, 344:119-130.
21. Harada S., Haneda E., Maekawa T., Morikawa Y., Funayama S., Nagata N., Ohtsuki K., Nagata N., Ohtsuki K. Casein kinase II (CK-II)-mediated stimulation of HIV-1 reverse transcriptase activity and characterization of selective inhibitors in vitro. Biol. Pharm. Bull. 1999, 22:1122-1126.
22. Honess R.W., Roizman B. Regulation of herpesvirus macromolecular synthesis I. Cascade regulation of the synthesis of three groups of viral proteins. J. Virol. 1974, 14:8-19.
23. Karaca G., Hargett D., McLean T.I., Aguilar J.S., Ghazal P., Wagner E.K., Bachenheimer S.L. Inhibition of the stress-activated kinase, p38, does not affect the virus transcriptional program of herpes simplex virus type 1. Virology 2004, 329:142-156.
24. Koffa M.D., Kean J., Zachos G., Rice S.A., Clements J.B. CK2 protein kinase is stimulated and redistributed by functional herpes simplex virus ICP27 protein. J. Virol. 2003, 77:4315-4325.
25. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
26. Lilley C.E., Chaurushiya M.S., Boutell C., Landry S., Suh J., Panier S., Everett R.D., Stewart G.S., Durocher D., Weitzman M.D. A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses. EMBO J. 2010, 29:943-955.
27. Ljubimov A.V., Caballero S., Aoki A.M., Pinna L.A., Grant M.B., Castellon R. Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2004, 45:4583-4591.
28. Lomonte P., Sullivan K.F., Everett R.D. Degradation of nucleosome-associated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0. J. Biol. Chem. 2001, 276:5829-5835.
29. Loret S., Guay G., Lippé R. Comprehensive characterization of extracellular herpes simplex virus type 1 virions. J. Virol. 2008, 82:8605-8618.
30. Meggio F., Pinna L.A. One-thousand-and-one substrates of protein kinase CK2?. FASEB J. 2003, 17:349-368.
31. Montenarh M. Cellular regulators of protein kinase CK2. Cell Tissue Res. 2010, 342:139-146.
32. Morrison E.E., Wang Y.F., Meredith D.M. Phosphorylation of structural components promotes dissociation of the herpes simplex virus type 1 tegument. J. Virol. 1998, 72:7108-7114.
33. Mossman K.L., Saffran H.A., Smiley J.R. Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J. Virol. 2000, 74:2052-2056.
34. O'Reilly D., Hanscombe O., O'Hare P. A single serine residue at position 375 of VP16 is critical for complex assembly with Oct-1 and HCF and is a target of phosphorylation by casein kinase II. EMBO J. 1997, 16:2420-2430.
35. Pagano M.A., Bain J., Kazimierczuk Z., Sarno S., Ruzzene M., Di Maira G., Elliott M., Orzeszko A., Cozza G., Meggio F., Pinna L.A. The selectivity of inhibitors of protein kinase CK2: an update. Biochem. J. 2008, 415:353.
36. Parkinson J., Lees-Miller S.P., Everett R.D. Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J. Virol. 1999, 73:650-657.
37. Potel C., Elliott G. Phosphorylation of the herpes simplex virus tegument protein VP22 has no effect on incorporation of VP22 into the virus but is involved in optimal expression and virion packaging of ICP0. J. Virol. 2005, 79:14057-14068.
38. Rojas S., Corbin-Lickfett K.A., Escudero-Paunetto L., Sandri-Goldin R.M. ICP27 phosphorylation site mutants are defective in herpes simplex virus 1 replication and gene expression. J. Virol. 2010, 84:2200-2211.
39. Rowe J., Greenblatt R.J., Liu D., Moffat J.F. Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice. Antiviral Res. 2010, 86:276-285.
40. Sacks W.R., Greene C.C., Aschman D.P., Schaffer P.A. Herpes simplex virus type 1 ICP27 is an essential regulatory protein. J. Virol. 1985, 55:796-805.
41. Samaniego L.A., Wu N., DeLuca N.A. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J. Virol. 1997, 71:4614-4625.
42. Sandri-Goldin R.M. The many roles of the regulatory protein ICP27 during herpes simplex virus infection. Front. Biosci. 2008, 13:5241-5256.
43. Scaglioni P.P., Yung T.M., Cai L.F., Erdjument-Bromage H., Kaufman A.J., Singh B., Teruya-Feldstein J., Tempst P., Pandolfi P.P. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 2006, 126:269-283.
44. Schaffer P.A., Aron G.M., Biswal N., Benyesh-Melnick M. Temperature-sensitive mutants of herpes simplex virus type 1: isolation, complementation and partial characterization. Virology 1973, 52:57-71.
45. Schang L.M., Phillips J., Schaffer P.A. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol. 1998, 72:5626-5637.
46. Smith K.O. Relationship between the envelope and the infectivity of herpes simplex virus. Proc. Soc. Exp. Biol. Med. 1964, 115:814-816.
47. Sun Z., Ren H., Liu Y., Teeling J.L., Gu J. Phosphorylation of RIG-I by casein kinase II inhibits its antiviral response. J. Virol. 2011, 85:1036-1047.
48. Wang S., Fischer P.M. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Biochem. Sci. 2008, 29:302-313.
49. Whalen S.G., Marcellus R.C., Barbeau D., Branton P.E. Importance of the Ser-132 phosphorylation site in cell transformation and apoptosis induced by the adenovirus type 5 E1A protein. J. Virol. 1996, 70:5373-5383.
50. Wisner T., Brunetti C., Dingwell K., Johnson D.C. The extracellular domain of herpes simplex virus gE is sufficient for accumulation at cell junctions but not for cell-to-cell spread. J. Virol. 2000, 74:2278-2287.
51. Xia K., Knipe D.M., DeLuca N.A. Role of protein kinase A and the serine-rich region of herpes simplex virus type 1 ICP4 in viral replication. J. Virol. 1996, 70:1050-1060.
52. Zhi Y., Sandri-Goldin R.M. Analysis of the phosphorylation sites of herpes simplex virus type 1 regulatory protein ICP27. J. Virol. 1999, 73:3246-3257.